Clinical Chemistry and Laboratory Medicine | January 31, 2023

Andreasson, Ulf, Gobom, Johan, Delatour, Vincent, Auclair, Guy, Noam, Yoav, Lee, Stephen, Wen, Jason, Jeromin, Andreas, Arslan, Burak, Maceski, Aleksandra, Willemse, Eline, Zetterberg, Henrik, Kuhle, Jens and Blennow, Kaj

Clinical Chemistry and Laboratory Medicine (CCLM), 2023

https://doi.org/10.1515/cclm-2022-1181

Abstract

Objectives

Neurofilament light chain (NfL) concentration in blood is a biomarker of neuro-axonal injury in the nervous system and there now exist several assays with high enough sensitivity to measure NfL in serum and plasma. There is a need for harmonization with the goal of creating a certified reference material (CRM) for NfL and an early step in such an effort is to determine the best matrix for the CRM. This is done in a commutability study and here the results of the first one for NfL in blood is presented.

Methods

Forty paired individual serum and plasma samples were analyzed for NfL on four different analytical platforms. Neat and differently spiked serum and plasma were evaluated for their suitability as a CRM using the difference in bias approach.

Results

The correlation between the different platforms with regards to measured NfL concentrations were very high (Spearman’s ρ≥0.96). Samples spiked with cerebrospinal fluid (CSF) showed higher commutability compared to samples spiked with recombinant human NfL protein and serum seems to be a better choice than plasma as the matrix for a CRM.

Conclusions

The results from this first commutability study on NfL in serum/plasma showed that it is feasible to create a CRM for NfL in blood and that spiking should be done using CSF rather than with recombinant human NfL protein.